Vedolizumab use is not associated with increased malignancy incidence: GEMINI LTS study results and post-marketing data.

Timothy R Card Ryan C UngaroFatima BhayatAimee BlakeGary HantsbargerSimon P L Travis

Published in: Alimentary pharmacology & therapeutics (2019)

The number of malignancies in the LTS study was similar to that expected from an IBD population with no statistically significant differences, although few confounders could be corrected for. Limitations of PM safety reporting require consideration; however, the number of malignancies with vedolizumab appeared low.

Keyphrases

ulcerative colitis
air pollution
emergency department
risk assessment
machine learning
patients with inflammatory bowel disease
adverse drug
drug induced